While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.
Mirati Therapeutics is continuing its bid to make its KRAS inhibitor candidate adagrasib a future market leader, presenting new Phase II data in patients with pancreatic and other gastrointestinal tumors.
Amgen’s Lumakras (sotorasib) became the first marketed KRAS inhibitor in May 2021, following a US approval in non-small cell lung cancer (NSCLC), but Mirati believes its drug will emerge as
In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
